# OnCo record nct04495296 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04495296/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04495296", "NCT04495296" ;
  schema:name "A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of CAPOX, Capecitabine, Paclitaxel / nab-paclitaxel in metastatic cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04495296/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04495296> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2020-08-13" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/tst001/> ;
  onco:companies <https://onco.cc/companies/transcenta/> .